Abstract: Sodium-glucose co-transporter protein (SGLT) is expressed in both intestinal epithelial cells and renal tubular epithelial cells, and it is linked to abdominal obesity, hypertension, type 2 diabetes, and renal diseases. Nutrients, hormones, inflammation, and oxidative stress all influence SGLT expression levels. SGLT inhibitors are brand-new diabetic medicines that also target gut and kidney. Studies have identified the renin-angiotensin system, renal sympathetic nerve activity, intestinal inflammation, gut microbes, and oxidative stress as potential mechanisms for the cardiorenal protective effects of SGLT inhibitors, in addition to benefits of weight loss and blood glucose reduction. The goal of this study is to find new ways to treat metabolic illnesses by targeting SGLT expression in the gut and kidney.

Key words: sodium-glucose co-transporter protein inhibitors, intestine, kidney